Positive data in phase 2 study of senolyti...
ambivalent 16 Aug 2022
https://www.ophthalm...tients-with-dme
The 12- and 18-week results indicate that a single injection of UBX1325 resulted in significantly greater letter gains and stabilization of retinal structure than the sham treatment, but also likely altered the disease trajectory of these patients who had been on anti-VEGF treatment,” he concluded. “We are greatly encouraged by these findings and look forward to our upcoming 24-week BEHOLD (DME) and 16-week ENVISION (wet AMD) study readouts in the months ahead.”
ambivalent 16 Aug 2022
A little rushed, I should have pasted:
"At 18-weeks, a primary analysis set of 54 patients, patients treated with UBX1325 had a mean improvement in BCVA of +6.1 ETDRS letters from baseline compared to +1.1 EDTRS letters in sham-treated patients (p = 0.0368). Patients treated with UBX1325 had a mean change in CST of +3.2 μm from baseline compared to +53.5 μm in sham-treated patients (p = 0.0719) "
CST ~ central subfield thickness.
ambivalent 23 Aug 2022
For anyone following this company, contempating investing - be warned.
ambivalent 01 Nov 2022
24 week data:
https://ir.unitybiot...ek-data-phase-2
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment
UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients
The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm
Edited by ambivalent, 01 November 2022 - 01:16 PM.